Restoring Blood Pressure in Hypertensive Mice Fails to Fully Reverse Vascular Stiffness.
hypertension
pulse wave velocity
reversal
vascular smooth muscle cells
vascular stiffness
Journal
Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
02
2020
accepted:
19
06
2020
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
8
2020
Statut:
epublish
Résumé
Hypertension is a well-established driver of vascular remodeling and stiffening. The goal of this study was to evaluate whether restoring normal blood pressure (BP) fully restores vascular stiffness toward that of normotensive controls. C57Bl6/J male mice received angiotensin II (angII; 1 μg/kg/min) via infusion pump for 8 weeks (hypertension group: HH), angII for 4 weeks (hypertension group: H4), angII for 4 weeks followed by 4 weeks of recovery (reversal group: HN), or sham treatment (normotensive group: NN). BP, heart rate, and pulse wave velocity (PWV) were measured longitudinally. At the end of the study period, aortas were harvested for testing of vasoreactivity, passive mechanical properties, and vessel structure. The HH group exhibited a sustained increase in BP and PWV over the 8-week period ( Hypertension causes a significant increase in
Sections du résumé
BACKGROUND
BACKGROUND
Hypertension is a well-established driver of vascular remodeling and stiffening. The goal of this study was to evaluate whether restoring normal blood pressure (BP) fully restores vascular stiffness toward that of normotensive controls.
METHODS
METHODS
C57Bl6/J male mice received angiotensin II (angII; 1 μg/kg/min) via infusion pump for 8 weeks (hypertension group: HH), angII for 4 weeks (hypertension group: H4), angII for 4 weeks followed by 4 weeks of recovery (reversal group: HN), or sham treatment (normotensive group: NN). BP, heart rate, and pulse wave velocity (PWV) were measured longitudinally. At the end of the study period, aortas were harvested for testing of vasoreactivity, passive mechanical properties, and vessel structure.
RESULTS
RESULTS
The HH group exhibited a sustained increase in BP and PWV over the 8-week period (
CONCLUSION
CONCLUSIONS
Hypertension causes a significant increase in
Identifiants
pubmed: 32792976
doi: 10.3389/fphys.2020.00824
pmc: PMC7385310
doi:
Types de publication
Journal Article
Langues
eng
Pagination
824Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL145132
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL148112
Pays : United States
Informations de copyright
Copyright © 2020 Steppan, Jandu, Savage, Wang, Kang, Narayanan, Nyhan and Santhanam.
Références
Methods Mol Med. 2005;108:91-104
pubmed: 16028678
Cardiovasc Pathol. 2013 Jan-Feb;22(1):9-15
pubmed: 22818581
Nat Rev Immunol. 2006 Jul;6(7):508-19
pubmed: 16778830
J Am Heart Assoc. 2017 Feb 3;6(2):
pubmed: 28159817
Circ Res. 2001 Nov 23;89(11):1073-80
pubmed: 11717166
Vasc Health Risk Manag. 2013;9:475-83
pubmed: 24039432
J Vasc Res. 2007;44(5):345-53
pubmed: 17713348
Expert Opin Pharmacother. 2010 Nov;11(16):2625-34
pubmed: 20977399
Am J Physiol Heart Circ Physiol. 2002 Nov;283(5):H1819-28
pubmed: 12384459
Hypertension. 2004 Sep;44(3):264-70
pubmed: 15262905
Physiol Rev. 2018 Jul 1;98(3):1627-1738
pubmed: 29873596
Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(1):H49-H59
pubmed: 31002285
Vasc Health Risk Manag. 2013;9:255-64
pubmed: 23745049
Hypertension. 2011 Nov;58(5):760-2
pubmed: 21947472
Hypertension. 2010 Jul;56(1):36-43
pubmed: 20530296
Arterioscler Thromb. 1994 Jul;14(7):1223-31
pubmed: 8018679
Hypertension. 2014 Aug;64(2):210-4
pubmed: 24799614
J Am Heart Assoc. 2014 Apr 10;3(2):e000599
pubmed: 24721796
J Vis Exp. 2018 Aug 20;(138):
pubmed: 30176012
Hypertension. 2013 Dec;62(6):1105-10
pubmed: 24060894
J Hypertens. 1999 Jan;17(1):1-4
pubmed: 10100086
J Clin Hypertens (Greenwich). 2012 Nov;14(11):773-8
pubmed: 23126349
Am J Physiol Heart Circ Physiol. 2013 Sep 15;305(6):H803-10
pubmed: 23873798
J Hypertens. 2001 Mar;19(3):381-7
pubmed: 11288807
Pulse (Basel). 2018 Mar;5(1-4):106-114
pubmed: 29761084
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Curr Hypertens Rep. 2018 Jul 6;20(9):76
pubmed: 29980951
Hypertension. 2013 Nov;62(5):934-41
pubmed: 24001897
Hypertension. 2002 Oct;40(4):511-5
pubmed: 12364355
J Atheroscler Thromb. 2005;12(3):175-80
pubmed: 16020919
Circ Res. 2010 Jul 9;107(1):117-25
pubmed: 20489165
Cardiovasc Res. 2018 Mar 15;114(4):513-528
pubmed: 29514201
J Hypertens. 2014 Aug;32(8):1606-12; discussion 1612
pubmed: 24886821
Cardiovasc Pathol. 2016 May-Jun;25(3):247-257
pubmed: 27031798
Methods Mol Biol. 2017;1614:69-73
pubmed: 28500596
Cardiol Res Pract. 2011;2011:263585
pubmed: 21845218
Am J Physiol. 1997 Jul;273(1 Pt 2):H494-500
pubmed: 9249523
Hypertension. 2015 Feb;65(2):252-6
pubmed: 25368028
Cardiovasc Res. 2001 Dec;52(3):372-86
pubmed: 11738054
J Biol Chem. 2002 Feb 1;277(5):3388-96
pubmed: 11729190
J Exp Med. 2007 Oct 1;204(10):2449-60
pubmed: 17875676
Circulation. 2005 Jun 28;111(25):3384-90
pubmed: 15967850
Hypertension. 2006 Sep;48(3):404-10
pubmed: 16908758
Cardiovasc Eng Technol. 2015 Mar;6(1):59-70
pubmed: 26577103
Curr Vasc Pharmacol. 2004 Oct;2(4):379-84
pubmed: 15320818
J Hypertens. 2015 Feb;33(2):330-8
pubmed: 25380150
Exp Cell Res. 2016 Apr 10;343(1):35-41
pubmed: 26518118
Circ Res. 2015 Apr 10;116(8):1448-61
pubmed: 25858068
Front Physiol. 2015 Nov 18;6:335
pubmed: 26635621
J Hypertens. 2011 Jun;29(6):1034-42
pubmed: 21519280
Stroke. 2012 Oct;43(10):2637-42
pubmed: 22879099
Sci Rep. 2016 Feb 17;6:20862
pubmed: 26883298